Form 8-K · Current report
AbbVie 8-K, filed Oct 15, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001104659-26-116227
Summary
AbbVie expanded its board of directors from twelve to thirteen members and appointed Dr. John M. Carethers as a Class II director on October 14, 2026. Carethers is vice chancellor for health sciences at the University of California San Diego, was previously a director of Avantor, and has been placed on AbbVie's Public Policy and Sustainability Committee.
Key points
- AbbVie's board grew from twelve directors to thirteen with the appointment of Dr. John M. Carethers as a Class II director.
- Carethers currently serves as vice chancellor for health sciences at the University of California San Diego and was previously a director of Avantor, Inc.
- Carethers was appointed to AbbVie's Public Policy and Sustainability Committee.
- The board determined Carethers is an independent director under NYSE Listed Company Manual section 303A.02 and AbbVie's governance guidelines, and he will receive independent-director compensation as disclosed in Exhibit 10.5 to AbbVie's Form 10-Q for the quarter ended March 31, 2025.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie. The Board affirmatively determined that Dr. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.